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Abstract Cerebral salt wasting syndrome (CSW-cerebral salt wasting) was first described in 
1950 by Peters. This syndrome can occur in patients who have sustained damage 
to the central nervous system (e.g. patients with subarachnoid bleeding, bacterial 
meningitis or after neurosurgery). Patients present with excessive natriuresis and 
hyponatremic dehydration.
Differentiating this syndrome with the syndrome of inappropriate antidiuretic 
hormone secretion (SIADH-syndrome of inappropriate antidiuretic hormone 
secretion), which may occur in the same group of patients, is necessary in order 
to administer the correct treatment which consists of fluid restriction and sodium 
replacement in SIADH and fluid and sodium replacement as well as occasional 
mineralocorticoid therapy in CSW. 
 
INTRODUCTION
Cerebral salt wasting syndrome (CSW) was first 
described by Peters et al. (1950). It consists of 
hyponatremia, which is accompanied by extracel-
lular volume depletion and renal sodium loss lead-
ing to increased diuresis in patients with various 
neurological disorders, in which disorders of the 
hypothalamic-pituitary-adrenal and thyroid axis 
have been excluded (Peters et al. 1950). However, 
after the publication by Schwartz et al. (1957) of 
the first description of syndrome of inappropri-
ate antidiuretic hormone secretion (SIADH-
syndrome of inappropriate antidiuretic hormone 
secretion), which is characterized by hyponatre-
mia, normovolemia and reduced urine output, 
it was discovered that most of the cases consid-
ered CSW so far met the diagnostic criteria for 
SIADH. Recent studies that have been published 
in the last years have provided a more precise 
characterization and a more detailed description 
of the etiopathogenesis of CSW and thus allowed 
for its differentiation with SIADH (Sivakumar 
et al. 1994; Damaraju et al.1997;Albanese et al. 
2001; Palmer 2003; DiIorgi et al. 2012). Treatment 
other than the one recommended for SIADH has 
also been proposed. CSW syndrome occurs most 
often in patients with stroke, intracerebral hemor-
rhage, subarachnoid hemorrhage and in patients 
after neurosurgical operations. It has also been 
reported in patients with tuberculous meningitis 
and increased intracranial pressure. In several pro-
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spective studies, it has also been found that CSW may 
occur more frequently than SIADH in patients after 
neurosurgical interventions (Palmer 2003). In a retro-
spective cohort study Hardesty et al. (2012) found that 
CSW occurred in 15/282 (5%) pediatric patients after 
brain tumor surgery and that there was a high incidence 
of neurological complications in the form of seizures in 
50% of the described patients with this syndrome.
CSW usually occurs within the first 10 days after 
subarachnoid hemorrhage, trauma, stroke or neu-
rosurgical intervention (Cerda-Esteve et al. 2008). 
Ruiz-Juretschkea et al. (2012) have speculated that 
hydrocephalus may play an important role in the 
pathogenesis of CSW. It is also believed that CSW due 
to the reduction of extracellular fluid volume second-
ary to renal sodium loss, may be a defense mechanism 
preventing the development of increased intracranial 
pressure in patients with subarachnoid hemorrhage, 
cerebral trauma or stroke (Johanson et al. 2006; Ruiz-
Juretschkea et al. 2012) In the differential diagnosis 
of hyponatremia with polyuria, excessive fluid intake 
and diuretics use in the postoperative period must be 
ruled out. It is also important to remember that CSW 
can coexist with diabetes insipidus (DI-diabetes insipi-
dus), and that polyuria secondary to natriuresis may be 
erroneously recognized as the result of a too low dose 
of desmopressin. In such cases, increasing the medica-
tion dose may escalate the hyponatremia (Albanese et 
al.2001). As presented in this case report, CSW can also 
occur in the course of complex three-phase (DI-DI/
CSW-DI) fluid and electrolyte disturbances following 
central nervous system (CNS) operations.
The relationship between CNS damage and renal salt 
wasting in CSW is unclear. 
It seems that the etiology of CSW is multifacto-
rial. Most authors agree that the primary pathogenetic 
mechanism is renal sodium loss leading to hyponatre-
mia and the reduction of extracellular fluid volume (Yee 
et al. 2010). A reduction in renal sympathetic nervous 
system activity may affect the reabsorption of sodium 
(Na+) in the renal proximal tubule and simultaneously 
lead to a reduction in the secretion of renin and aldo-
sterone despite a decrease in extracellular fluid volume 
(Berendes et al. 1997; Palmer 2003; Cerda-Esteve et al. 
2008). Furthermore a possible involvement of natri-
uretic peptides is being considered in the etiology of 
CSW as well (Cerda-Esteve et al. 2008 ). They fulfil a 
regulatory role in the process of ion homeostasis in the 
cerebrospinal fluid, and several studies using animal 
models have demonstrated that they have an impact 
on the reduction of intracranial pressure and cerebral 
edema (Minamikawa et al. 1994; Akdemir et al. 1997). 
Atrial (ANP-atrial natriuretic peptide) and brain (BNP-
brain natriuretic peptide) natriuretic peptides directly 
inhibit Na+ reabsorption in the proximal tubule and 
indirectly increase natriuresis by suppressing the renin-
angiotensin-aldosterone axis (Steele et al. 1991; Levin 
et al. 1998; Yee et al. 2010). BNP which is produced in 
the cardiac ventricles and the hypothalamus is consid-
ered the most likely natriuretic peptide mediating CSW 
(Berendes et al. 1997; Levin et al. 1998). In patients 
with subarachnoid hemorrhage and cerebral trauma, 
increased concentrations of ANP and BNP in the 
serum and cerebrospinal fluid along with an increase in 
intracranial pressure were found (Berendes et al. 1997; 
Yamasaki et al. 1997; Kirchhoff et al. 2006; Sviri et al. 
2006). Johanson et al. (2006) demonstrated that ANP 
decreases the production of cerebrospinal fluid in acute 
hydrocephalus. It is not clear whether the determina-
tion of serum natriuretic peptides and ADH may be 
useful in the differential diagnosis of hyponatremia in 
SIADH and CSW (Berkenbosch et al. 2002; Singh et al. 
2002; Cole et al. 2004; Jimenez et al. 2006).
In this case report we present a patient who expe-
rienced fluid and electrolyte disturbances, including 
CSW in the postoperative period.
CASE PRESENTATION
A 22-year-old patient with hydrocephalus caused by 
congenital toxoplasmosis, after multiple ventriculo-
peritoneal shunt replacements due to the necessity of 
its extension as a result of the growth of the patient and 
occlusion was re-admitted to the Neurosurgery Depart-
ment for his next scheduled shunt replacement. 
The operation was complicated by intraventricu-
lar bleeding. In the first postoperative day, laboratory 
results showed a slight hypernatraemia (serum Na: 
150 mmol/l (n: 135–145 mmol/l), with a low urine spe-
cific gravity (1.0 g/ml), an increased serum osmolality 
of 298 mOsm/kg H2O, decreased urine osmolality of 
180 mOsm/kg H2O, increased diuresis 5,200 ml/day 
and polydipsia. On the basis of these results, the patient 
was diagnosed with central DI (cDI), and received des-
mopressin at a dose of 0.1 mg twice a day, resulting in 
clinical improvement and normalization of fluid and 
electrolyte abnormalities (serum Na: 140 mmol/l, urine 
specific gravity: 1.015 g/ml, normalization of serum and 
urine osmolality and a reduction in diuresis, (Figure 1). 
On the 13th postoperative day hyponatremia (serum 
Na: 116 mmol/l) and polyuria (4,900 ml/day) were 
found. The desmopressin dose was reduced to 0.05 mg 
p.o. twice a day. In a clinical evaluation the patient 
was conscious, dehydrated, reporting dizziness upon 
standing as evidenced by orthostatic hypotension and 
a blood pressure of 90/60 mmHg. Laboratory tests also 
showed increased natriuresis: sodium excretion in the 
urine: 542 mmol/24 hours (N: 40–220), which amounts 
to 5.8 mmol/kg/day (n: 2.6±0.5), a negative sodium bal-
ance: (–) 277 mmol/l/24 h, equal to >3 mmol/kg/24 h, 
decreased serum osmolality (255 mOsm/kg H2O), 
normal urine osmolality (293 mOsm/kg H2O), and a 
ratio of urine osmolality to serum osmolality of 1.15. 
Decreased levels of uric acid (85 mmol/l, n: 180–506), 
increased hematocrit (54%, n: 41–53), urea level at 
the upper limit of normal (6.7 mmol/l, n: 3.2–7.1) and 
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decreased levels of aldosterone (38 pg/ml, n: 55–160) 
were also found.
Due to normal plasma renin activity: 0.38 pg/ml/h 
(n: 0.2–2.8) and cortisol levels: 137.2 ng/ml (n: 50–230) 
adrenal insufficiency was excluded. Normal TSH 
(1.87 mIU/mL, n: 0.4–4.2) and fT4 levels (16.7 pmol/l, 
n: 10–25) allowed the exclusion of hypothyroidism as 
a cause of hyponatremia as well. Until adrenal insuf-
ficiency was ultimately excluded the patient was treated 
for 2 days with hydrocortisone, during this time we did 
not observe any significant changes in natremia or an 
increased urine volume. Desmopressin was maintained 
at a reduced dose (0.05 mg twice a day), fluids and elec-
trolytes were supplemented. In the absence of improve-
ment with fluid and sodium supplementation alone, 
fludrocortisone was introduced at a dose of 0.05 mg 
twice a day resulting in clinical improvement and 
normalisation of biochemical parameters. The patient 
was discharged home on postoperative day 40. Outpa-
tient fludrocortisone was discontinued after a month, 
without any changes in natremia, however an attempt 
to withdraw desmopressin resulted in an increase in 
diuresis and a tendency towards hypernatremia, which 
indicated persistent DI in our patient (Figure 1).
DISCUSSION
This case describes a 22 year-old patient with a rare 
three-phase fluid and electrolyte disorder which 
occurred after neurosurgery comprising of: Central DI 
in the first phase, then the coincidence of CSW and DI 
in the second phase and persistent DI in the last phase 
[Fig. 1]. The diagnosis of central DI was based on the 
following criteria: (1) polydipsia and polyuria found in 
a 24 hour fluid balance, (2) hypernatremia and plasma 
hyperosmolality, (3) decreased urine osmolality which 
was lower than serum osmolality, (4) low urine spe-
cific gravity and clinical and biochemical improvement 
after the administration of desmopressin (DiIorgi et 
al. 2012). In the differential diagnosis of hyponatre-
mia (which occurred in the second phase) we ruled 
out excessive fluid intake in the postoperative period, 
too high of a dose of desmopressin in the treatment of 
transient DI, liver failure, heart failure, adrenal insuffi-
ciency, hypothyroidism and side effects of antiepileptic 
drugs (Albanese et al. 2001). In the differential diagno-
sis of hyponatremic hypovolemia which was reported 
in the patient at a later stage, extrarenal loss of extra-
cellular fluid, diuretics, nephropathy with the loss of 
sodium and osmotic diuresis were taken into account 
(Di Iorgi et al. 2012). In the broader differential diagno-
sis of natriuresis SIADH, CSW and the coincidence of 
CSW and DI were included (Albanese et al. 2001; Beu-
khof et al. 2007; Rahman & Friedman 2009) (Table 1).
SIADH and CSW occur as a complication of the 
same type of damage to the CNS and in a similar time 
period (3–10 days after neurosurgery or trauma to 
the CNS) (Di Iorgi et al. 2012). Patients in these two 
disorders present with hyponatremia and increased 
natriuresis, and the differences between the two syn-
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Fig. 1. Clinical and biochemical observation of patient. DDAVP, desmopressin. Arrows 
present start or stop of therapy.
Tab. 1. CSW and SIADH – differential diagnosis 
(Albanese et al. 2001; Hannon & Thompson 2010). 
CSW SIADH
Central venous 
pressure
↓ N
Blood pressure ↓, orthostatic 
hypotension
N
Body weight N or ↓ N or ↑
Thirst ↑ N
Urine volume N/↑ N/↓
Creatinine in serum N/↓ N/↑
[Na+] in serum ↓ ↓
[Na+] in urine ↑ ↑
urea N/↑ N/↓
Plasma renine 
activity
N, ↑, ↓ ↓
AVP ↑ ↑ N/↑
ANP, BNP ↑ ↑ N/↑
↓-decreased, ↑-increased, N-normal, ANP - atrial 
natriuretic peptide, BNP - brain natriuretic peptide, 
AVP - arginine vasopressin
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dromes are minimal. It is important to answer the ques-
tion if the primary reason for low sodium in the serum 
is water intoxication in the course of SIADH (relative 
hyponatremia) or severe loss of sodium ions in the 
urine (absolute hyponatremia) in the course of CSW 
(Di Iorgi et al. 2012 ). Diuresis is increased in CSW 
(Table 1) and SIADH, but in this second disorder it may 
also be normal or reduced, and therefore the absence 
or presence of polyuria cannot be the main criterion 
for differentiating these two states. The concentration 
of uric acid is decreased in both diseases. It is believed 
that increased fractional excretion of uric acid in CSW 
is a result of impaired reabsorption of Na+ in the proxi-
mal tubule, while in SIADH it is due to an increase in 
extracellular fluid volume (Maesaka et al. 1992; Palmer 
et al. 2003; Sterns & Silver 2008; Bitew et al. 2009). 
In clinical practice, the most important criterion 
differentiating CSW from SIADH remains extracellu-
lar fluid volume assessment (ECF, extracellular fluid), 
which is increased in SIADH and decreased in CSW. In 
order to accurately assess the ECF volume and establish 
the diagnosis of CSW invasive central venous pressure 
monitoring is recommended (Damaraju et al. 1997; 
Albanese et al. 2001; Cerda-Esteve et al. 2008; Rahman 
& Friedman 2009). Invasive methods of assessing 
volemia however are not routinely used in the postop-
erative period, since usually, at least in our centre, the 
patient is no longer in the intensive care unit 48–72 
hours after neurosurgery. According to some authors 
it may be helpful to assess hematocrit and urea levels 
which are elevated in CSW and indicate dehydration in 
the patient and normal in SIADH where normovolemia 
is common (Brook & Brown 2008).
The diagnosis of CSW in this patient was based on 
clinical features such as dehydration, low blood pres-
sure, symptoms of orthostatic hypotension, elevated 
hematocrit, and urea levels (indirectly indicating a 
reduction in extracellular fluid volume), increased 
diuresis and biochemical indicators such as hypona-
tremia with natriuresis and a negative sodium balance 
(Table 1).
An argument against the diagnosis of SIADH in this 
patient was the presence of dehydration. In contrast 
to SIADH, which is caused by the inadequate secre-
tion of ADH or hyperactive vasopressin receptors in 
the kidneys, leading to water retention and euvolemic 
or hypervolemic hyponatremia, in CSW hypovolemic 
hyponatremia is due to the loss of both sodium ions and 
water (Kinik et al. 2001; Yee et al. 2010; Ozdemir et al. 
2010).
Determining the cause of hyponatremia was impor-
tant in this case because of the differences in treatment 
regimens. In SIADH therapy is based on fluid restric-
tion and the slow administration of hypertonic saline 
solution. Fluid restriction is contraindicated in CSW 
as it may worsen hypovolemia and cause hypotension, 
cerebral vasospasm, ischemia and/or infarction of the 
brain tissue (Hickey 2009). In CSW fluids are supple-
mented with 0.9% and 3% sodium chloride. 3% sodium 
chloride solution should be administered slowly, not 
exceeding the maximum limit of correction of sodium 
<12 mmol/l/day, as a rapid correction of hyponatremia 
can cause myelinolysis syndrome of the CNS (Hickey 
2009; Mortimer & Jancik 2006; Ozdemir et al. 2010). 
When possible, fluids and electrolytes should be sup-
plemented orally as it was done in this patient. 
Additional tests also showed a decrease in aldoste-
rone levels. The patient received fludrocortisone yield-
ing an improvement in his fluid, electrolyte and clinical 
status. Fludrocortisone is a synthetic corticosteroid 
with moderate glucocorticoid and predominant min-
eralocorticoid potency which reduces the loss of renal 
sodium by increasing its resorption in the renal proxi-
mal tubule (Ishikawa et al. 1987; Rahman & Friedman 
2009; Momi et al. 2010). Fludrocortisone is used for 
aldosterone substitution in various forms of primary 
adrenal insufficiency such as Addison’s disease, clas-
sic salt-wasting form of congenital adrenal hyperpla-
sia and isolated adrenal mineralocorticoid deficiency. 
The benefits of fludrocortisone in CSW have also been 
described (Ishikawa et al. 1987; Momi et al. 2010). 
Fludrocortisone doses range from 0.05 to 0.1 mg, with 
the possibility of increasing the dose to 0.4 mg a day in 
divided doses (Albanese et al. 2001; Taplin et al. 2006; 
Min Jeong Choi et al. 2012).
Because of persistent polyuria in this patient 
(Figure 1), we suspected the possibility of coincidence 
of CSW and DI, which is why the treatment in the 
second phase of the electrolyte disturbances consisted 
of desmopressin maintained at lower dose as well as 
oral supplementation of sodium and fluids (Albanese 
et al. 2001).
SUMMARY
Hyponatremia is the most common electrolyte disorder 
in hospitalised patients with various neurosurgical dis-
orders appearing in about 15% of them (Palmer 2003; 
Mirski & Verales 2008; Hardesty et al. 2012). Hypo-
natremia in the postoperative neurosurgical patient 
may lead to a lower threshold for seizures. Given that 
seizures in neurosurgical patients can lead to further 
damage to the brain tissue increasing morbidity and 
mortality in the postoperative course, determining the 
cause of hyponatremia is important because of the dif-
ferent therapeutic approaches. The differential diagno-
sis should also take into account the occurrence of the 
rare cerebral salt wasting syndrome.
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